Opyl (ASX:OPL) signed a service level agreement with Avion, a full-service contract research organization that delivers end-to-end clinical trial solutions, the company said in a Friday Australian bourse filing.
The partnership combines Avion's expertise in clinical trial management with Opyl's proprietary TrialKey platform, delivering data-driven insights to optimize trial design and improve outcomes, the filing said.
Under the agreement, Opyl and Avion will integrate Opyls's proprietary TrialKey platform into clinical trial planning and execution, and the company will provide Avion with reports and insights for AU$5,000 per report, according to the filing.